开发 1 型糖尿病联合免疫疗法：来自 ITN-JDRF 1 型糖尿病联合治疗评估小组的建议。
Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group.
机构信息
Immune Tolerance Network, San Francisco, CA 94107, USA.
出版信息
Clin Exp Immunol. 2010 May;160(2):176-84. doi: 10.1111/j.1365-2249.2010.04153.x.
Abstract
Like many other complex human disorders of unknown aetiology, autoimmune-mediated type 1 diabetes may ultimately be controlled via a therapeutic approach that combines multiple agents, each with differing modes of action. The numerous advantages of such a strategy include the ability to minimize toxicities and realize synergies to enhance and prolong efficacy. The recognition that combinations might offer far-reaching benefits, at a time when few single agents have yet proved themselves in well-powered trials, represents a significant challenge to our ability to conceive and implement rational treatment designs. As a first step in this process, the Immune Tolerance Network, in collaboration with the Juvenile Diabetes Research Foundation, convened a Type 1 Diabetes Combination Therapy Assessment Group, the recommendations of which are discussed in this Perspective paper.
摘要
与许多其他病因不明的复杂人类疾病一样，自身免疫介导的 1 型糖尿病最终可能通过一种联合治疗方法得到控制，这种方法结合了多种具有不同作用机制的药物。这种策略有许多优点，包括能够最大限度地减少毒性并实现协同作用，以增强和延长疗效。在很少有单一药物在大型试验中证明有效的情况下，认识到联合治疗可能带来深远的益处，这对我们构思和实施合理治疗方案的能力构成了重大挑战。作为这一过程的第一步，免疫耐受网络与青少年糖尿病研究基金会合作，召集了 1 型糖尿病联合治疗评估小组，本文讨论了该小组的建议。
相似文献
1
Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group.开发 1 型糖尿病联合免疫疗法：来自 ITN-JDRF 1 型糖尿病联合治疗评估小组的建议。
Clin Exp Immunol. 2010 May;160(2):176-84. doi: 10.1111/j.1365-2249.2010.04153.x.
2
[One step towards restoration of self-tolerance in human autoimmune diseases].[迈向人类自身免疫性疾病自身耐受恢复的一步]
Med Sci (Paris). 2007 Feb;23(2):167-71. doi: 10.1051/medsci/2007232167.
3
Type 1 diabetes.1型糖尿病
Nat Rev Drug Discov. 2010 Mar;9(3):187-8. doi: 10.1038/nrd3097.
4
A Preclinical Consortium Approach for Assessing the Efficacy of Combined Anti-CD3 Plus IL-1 Blockade in Reversing New-Onset Autoimmune Diabetes in NOD Mice.一种评估联合抗CD3加白细胞介素-1阻断在逆转非肥胖糖尿病（NOD）小鼠新发自身免疫性糖尿病中疗效的临床前联合研究方法。
Diabetes. 2016 May;65(5):1310-6. doi: 10.2337/db15-0492. Epub 2015 Dec 30.
5
The role of B lymphocytes as key antigen-presenting cells in the development of T cell-mediated autoimmune type 1 diabetes.B淋巴细胞作为关键抗原呈递细胞在T细胞介导的自身免疫性1型糖尿病发生发展中的作用。
Curr Dir Autoimmun. 2003;6:212-27. doi: 10.1159/000066863.
6
DiaPep277® and immune intervention for treatment of type 1 diabetes.DiaPep277® 和免疫干预治疗 1 型糖尿病。
Clin Immunol. 2013 Dec;149(3):307-16. doi: 10.1016/j.clim.2013.09.001. Epub 2013 Sep 11.
7
Intervention therapies for insulin-dependent diabetes.胰岛素依赖型糖尿病的干预疗法。
Autoimmunity. 1993;16(4):301-10. doi: 10.3109/08916939309014650.
8
Immunopathogenesis and immunotherapeutic approaches to type 1A diabetes.1A型糖尿病的免疫发病机制及免疫治疗方法
Expert Opin Biol Ther. 2004 Oct;4(10):1569-75. doi: 10.1517/14712598.4.10.1569.
9
Anti-CD3/Anti-CXCL10 Antibody Combination Therapy Induces a Persistent Remission of Type 1 Diabetes in Two Mouse Models.抗 CD3/抗 CXCL10 抗体联合治疗在两种小鼠模型中诱导 1 型糖尿病的持续缓解。
Diabetes. 2015 Dec;64(12):4198-211. doi: 10.2337/db15-0479. Epub 2015 Aug 20.
10
What will it take to get therapies approved for type 1 diabetes?要使治疗方法获批用于1型糖尿病需要什么条件？
Ann N Y Acad Sci. 2008 Dec;1150:25-31. doi: 10.1196/annals.1447.043.
引用本文的文献
1
-Based Vaccine: A Promising Strategy for Type 1 Diabetes.基于疫苗：1型糖尿病的一种有前景的策略。
Vaccines (Basel). 2025 Apr 14;13(4):405. doi: 10.3390/vaccines13040405.
2
Therapy concepts in type 1 diabetes mellitus treatment: disease modifying versus curative approaches.1 型糖尿病治疗中的治疗理念：疾病修饰与治愈方法。
J Mol Med (Berl). 2024 Dec;102(12):1451-1455. doi: 10.1007/s00109-024-02494-w. Epub 2024 Oct 18.
3
Discordant Effects of Polyamine Depletion by DENSpm and DFMO on β-cell Cytokine Stress and Diabetes Outcomes in Mice.多胺耗竭剂 DENSpm 和 DFMO 对小鼠β细胞细胞因子应激和糖尿病结局的拮抗作用。
Endocrinology. 2024 Jan 16;165(3). doi: 10.1210/endocr/bqae001.
4
Nivolumab-induced diabetes mellitus-a case report with literature review of the treatment options.纳武利尤单抗致糖尿病病例报告及治疗选择的文献复习
Front Immunol. 2023 Oct 26;14:1248919. doi: 10.3389/fimmu.2023.1248919. eCollection 2023.
5
A first-in-human, open-label Phase 1b and a randomised, double-blind Phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumab.一项在近期发生 1 型糖尿病患者中进行的、以 AG019 作为单药治疗和联合 teplizumab 治疗的、首例人体、开放性标签的 1b 期和随机、双盲的 2a 期临床试验。
Diabetologia. 2024 Jan;67(1):27-41. doi: 10.1007/s00125-023-06014-2. Epub 2023 Oct 2.
6
A Plasma miR-193b-365 Signature Combined With Age and Glycemic Status Predicts Response to Lactococcus lactis-Based Antigen-Specific Immunotherapy in New-Onset Type 1 Diabetes.血浆 miR-193b-365 特征与年龄和血糖状态相结合可预测新型 1 型糖尿病中基于乳球菌的抗原特异性免疫治疗的反应。
Diabetes. 2023 Oct 1;72(10):1470-1482. doi: 10.2337/db22-0852.
7
Combination therapy with lansoprazole and cholecalciferol is associated with a slower decline in residual beta-cell function and lower insulin requirements in children with recent onset type 1 diabetes: results of a pilot study.兰索拉唑和胆钙化醇联合治疗与近期发病 1 型糖尿病儿童残余β细胞功能下降速度较慢和胰岛素需求降低相关：一项初步研究的结果。
Einstein (Sao Paulo). 2022 Nov 25;20:eAO0149. doi: 10.31744/einstein_journal/2022AO0149. eCollection 2022.
8
Proinflammatory signaling in islet β cells propagates invasion of pathogenic immune cells in autoimmune diabetes.胰岛β细胞中的促炎信号转导促进自身免疫性糖尿病中致病性免疫细胞的浸润。
Cell Rep. 2022 Jun 28;39(13):111011. doi: 10.1016/j.celrep.2022.111011.
9
New Developments in T Cell Immunometabolism and Therapeutic Implications for Type 1 Diabetes.T 细胞免疫代谢的新进展及其对 1 型糖尿病的治疗意义。
Front Endocrinol (Lausanne). 2022 Jun 10;13:914136. doi: 10.3389/fendo.2022.914136. eCollection 2022.
10
Personalized Immunotherapies for Type 1 Diabetes: Who, What, When, and How?1型糖尿病的个性化免疫疗法：对象、内容、时机及方式？
J Pers Med. 2022 Mar 29;12(4):542. doi: 10.3390/jpm12040542.
本文引用的文献
1
Surrogate end points in the design of immunotherapy trials: emerging lessons from type 1 diabetes.免疫治疗试验设计中的替代终点：1 型糖尿病带来的新教训。
Nat Rev Immunol. 2010 Feb;10(2):145-52. doi: 10.1038/nri2705.
2
Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes.霉酚酸酯和达克珠单抗联合治疗新发 1 型糖尿病患者β细胞功能丧失。
Diabetes Care. 2010 Apr;33(4):826-32. doi: 10.2337/dc09-1349. Epub 2010 Jan 12.
3
Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.利妥昔单抗、B淋巴细胞清除与β细胞功能的保留
N Engl J Med. 2009 Nov 26;361(22):2143-52. doi: 10.1056/NEJMoa0904452.
4
Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes.艾塞那肽单药及联合地昔单抗治疗对长期 1 型糖尿病患者胰岛β细胞功能的影响。
Diabetes Care. 2009 Dec;32(12):2251-7. doi: 10.2337/dc09-0773. Epub 2009 Oct 6.
5
Genetic-induced variations in the GAD65 T-cell repertoire governs efficacy of anti-CD3/GAD65 combination therapy in new-onset type 1 diabetes.遗传诱导的 GAD65 T 细胞库变化可调控抗 CD3/GAD65 联合治疗新诊断 1 型糖尿病的疗效。
Mol Ther. 2010 Feb;18(2):307-16. doi: 10.1038/mt.2009.197. Epub 2009 Aug 18.
6
Validity and reproducibility of measurement of islet autoreactivity by T-cell assays in subjects with early type 1 diabetes.胰岛自身反应性 T 细胞检测在早期 1 型糖尿病患者中的测量的有效性和可重复性。
Diabetes. 2009 Nov;58(11):2588-95. doi: 10.2337/db09-0249. Epub 2009 Aug 12.
7
Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.采用单疗程抗CD3单克隆抗体替普珠单抗治疗新发1型糖尿病患者，可使胰岛素分泌维持长达5年。
Clin Immunol. 2009 Aug;132(2):166-73. doi: 10.1016/j.clim.2009.04.007. Epub 2009 May 14.
8
How can we improve the translational landscape for a faster cure of type 1 diabetes?我们如何改善转化医学前景以更快治愈1型糖尿病？
J Clin Invest. 2009 May;119(5):1061-5. doi: 10.1172/jci37593.
9
Analysis of islet inflammation in human type 1 diabetes.人类1型糖尿病中胰岛炎症的分析。
Clin Exp Immunol. 2009 Feb;155(2):173-81. doi: 10.1111/j.1365-2249.2008.03860.x.
10
Post-mortem analysis of islet pathology in type 1 diabetes illuminates the life and death of the beta cell.1型糖尿病胰岛病理的尸检分析揭示了β细胞的生死。
Clin Exp Immunol. 2009 Feb;155(2):125-7. doi: 10.1111/j.1365-2249.2008.03864.x.
Zotero 插件